Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy.
The receptors for IGF-I (IGF-IR) and insulin (IR) have been implicated in physiological cardiac growth, but it is unknown whether IGF-IR or IR signaling are critically required. We generated mice with cardiomyocyte-specific knockout of IGF-IR (CIGF1RKO) and compared them with cardiomyocyte-specific insulin receptor knockout (CIRKO) mice in response to 5 wk exercise swim training. Cardiac development was normal in CIGF1RKO mice, but the hypertrophic response to exercise was prevented. In contrast, despite reduced baseline heart size, the hypertrophic response of CIRKO hearts to exercise was preserved. Exercise increased IGF-IR content in control and CIRKO hearts. Akt phosphorylation increased in exercise-trained control and CIRKO hearts and, surprisingly, in CIGF1RKO hearts as well. In exercise-trained control and CIRKO mice, expression of peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) and glycogen content were both increased but were unchanged in trained CIGF1RKO mice. Activation of AMP-activated protein kinase (AMPK) and its downstream target eukaryotic elongation factor-2 was increased in exercise-trained CIGF1RKO but not in CIRKO or control hearts. In cultured neonatal rat cardiomyocytes, activation of AMPK with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) prevented IGF-I/insulin-induced cardiomyocyte hypertrophy. These studies identify an essential role for IGF-IR in mediating physiological cardiomyocyte hypertrophy. IGF-IR deficiency promotes energetic stress in response to exercise, thereby activating AMPK, which leads to phosphorylation of eukaryotic elongation factor-2. These signaling events antagonize Akt signaling, which although necessary for mediating physiological cardiac hypertrophy, is insufficient to promote cardiac hypertrophy in the absence of myocardial IGF-I signaling.
Kim
Jaetaek
J
Program in Human Molecular Biology and Genetics, University of Utah, Salt Lake City, Utah 84112, USA.
Wende
Adam R
AR
Sena
Sandra
S
Theobald
Heather A
HA
Soto
Jamie
J
Sloan
Crystal
C
Wayment
Benjamin E
BE
Litwin
Sheldon E
SE
Holzenberger
Martin
M
LeRoith
Derek
D
Abel
E Dale
ED
D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D006332:Cardiomegaly / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology*; D049108:Cell Enlargement / Q000187:drug effects; D002478:Cells, Cultured; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008955:Models, Cardiovascular; D009200:Myocardial Contraction; D032383:Myocytes, Cardiac / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D020652:Peptide Elongation Factor 2 / Q000378:metabolism; D005082:Physical Exertion; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D017526:Receptor, IGF Type 1 / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D011972:Receptor, Insulin / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D012265:Ribonucleotides / Q000494:pharmacology; D015398:Signal Transduction; D013550:Swimming
D020652:Peptide Elongation Factor 2; D012265:Ribonucleotides; D000620:Aminoimidazole Carboxamide; D017526:Receptor, IGF Type 1; D011972:Receptor, Insulin; D051057:Proto-Oncogene Proteins c-akt; D055372:AMP-Activated Protein Kinases; C031143:AICA ribonucleotide
Am J Physiol. 1994 Sep;267(3 Pt 2):H1167-73
8092282
J Biol Chem. 2004 Sep 17;279(38):39593-603
15262994
Int J Cancer. 2005 Apr 20;114(4):668-72
15609331
Mol Cell Biol. 2005 Nov;25(21):9491-502
16227599
FASEB J. 2006 Apr;20(6):773-5
16484330
Circulation. 2006 May 2;113(17):2097-104
16636172
Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2409-16
16415076
J Physiol. 2006 Jul 1;574(Pt 1):95-112
16690706
Nat Rev Mol Cell Biol. 2006 Aug;7(8):589-600
16936699
Can J Physiol Pharmacol. 2006 Jul;84(7):725-37
16998536
J Biol Chem. 2006 Oct 27;281(43):32841-51
16950770
Genes Dev. 2006 Dec 15;20(24):3347-65
17182864
Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E145-50
16926385
Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):612-7
17202264
FASEB J. 1999 Nov;13(14):1923-9
10544175
J Clin Invest. 1999 Dec;104(12):1703-14
10606624
EMBO J. 2000 Jun 1;19(11):2537-48
10835352
EMBO J. 2000 Dec 1;19(23):6341-50
11101507
Mol Cell Biol. 2001 Feb;21(3):952-65
11154281
Endocrinology. 2001 Sep;142(9):3749-55
11517150
Nature. 2001 Sep 13;413(6852):179-83
11557984
Circ Res. 2001 Nov 23;89(11):977-82
11717153
J Clin Invest. 2002 Mar;109(5):629-39
11877471
Development. 2002 Oct;129(19):4591-603
12223415
J Biol Chem. 2002 Oct 4;277(40):37670-7
12163490
Growth Horm IGF Res. 2003 Feb;13(1):19-25
12550078
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1711-6
12578979
Hypertension. 2007 May;49(5):962-70
17389260
J Biol Chem. 2007 Jun 29;282(26):18793-9
17488713
Diabetes. 2007 Oct;56(10):2457-66
17623815
Cell Metab. 2007 Oct;6(4):294-306
17908558
Endocrinology. 2007 Dec;148(12):6047-53
17823261
J Biol Chem. 2007 Dec 14;282(50):36642-51
17932032
Circulation. 2008 Mar 18;117(11):1414-22
18316483
Diabetes. 2003 Mar;52(3):642-9
12606503
Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E629-36
12759223
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12355-60
14507992
J Biol Chem. 2004 Feb 6;279(6):4782-93
14597618
J Biol Chem. 2004 Mar 26;279(13):12220-31
14709557
Mol Cell. 2004 May 7;14(3):395-403
15125842
J Biol Chem. 2004 Jul 30;279(31):32771-9
15159410
Nature. 1999 Aug 5;400(6744):581-5
10448862